PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY

以患者为中心的皮肤肿瘤学研究

• 批准号: 6511818
• 负责人: STUART R LESSIN
• 金额: $ 11.82万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6511818
• 关键词: clinical research; clinical trials; curriculum; education evaluation /planning; health science research potential; human subject; human therapy evaluation; medical education; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; oncology; peptide analog; skin neoplasms; vector vaccine

This is a Midcareer Investigator Award in Patient-Oriented Research (POR) application (K24) for Stuart R. Lessin, M.D and will focus on cutaneous oncology. Dr. Lessin is Associate Professor and Co-Director of the Cutaneous Lymphoma Program in the Department of Dermatology at the University of Pennsylvania. He is highly committed to POR and has a well established track record (funding and publications) in the area of cutaneous T-cell lymphoma (CTCL). He has developed techniques for the molecular diagnosis of lymphoproliferative skin diseases based on T-cell receptor (TCR) gene expression and translated them into new strategies of therapy utilizing the TCR as a target. Dr. Lessin is currently the principal investigator of a FDA funded Phase I clinical trial testing the safety and efficacy of genetic (DNA) vaccination of human TCR in patients with CTCL. The overall research goal of this proposal will be to develop and test novel therapeutic approaches to skin cancers utilizing the technologies of therapeutic DNA vaccines, peptide vaccines and peptidomimetics. Dr. Lessin has been heavily involved in the mentoring and training of trainees in POR at all levels - medical students, residents/fellows and junior faculty. This has been accomplished through a series of well established POR programs. Currently, Dr. Lessin serves as a mentor in the Department of Dermatology's Cutaneous Oncology Fellowship Program, NIH Training Grant (T32), Drug Study Unit, Derm 800 Research elective and Junior Faculty Mentor's Program. The University of Pennsylvania's commitment and ability to provide opportunities and facilities necessary for POR is extraordinary. A well established Core Curriculum in POR Training, a NIH sponsored General Clinical Research Center (GCRC) and outstanding interaction between basic and clinical investigators provides a unique and dynamic environment in which to conduct and train individuals in POR. Dr. Lessin will participate in the POR core curriculum and the GCRC. This award will provide a critical infrastructure for Dr. Lessin to pursue POR and to mentor other investigators in POR. A commitment of 50 percent effort will ensure the continued acquisition of funding and protected time for clinical testing of new therapies. Furthermore, it will enable Dr. Lessin to continue to participate in the ongoing departmental and institutional POR programs and serve as a role model and mentor for young investigators in POR at the University of Pennsylvania.

这是斯图尔特·R·莱辛医学博士在以患者为中心的研究(POR)应用(K24)方面的职业中期研究人员奖，将专注于皮肤肿瘤学。莱辛博士是宾夕法尼亚大学皮肤科皮肤淋巴瘤项目的副教授兼联席主任。他高度致力于POR，并在皮肤T细胞淋巴瘤(CTCL)领域拥有良好的记录(资金和出版物)。他开发了基于T细胞受体(TCR)基因表达的淋巴增生性皮肤病的分子诊断技术，并将其转化为以TCR为靶点的新治疗策略。莱辛博士目前是FDA资助的一项第一阶段临床试验的首席研究员，该试验测试了人类TCR基因疫苗在CTCL患者中的安全性和有效性。这项提案的总体研究目标将是利用治疗性DNA疫苗、多肽疫苗和多肽学技术开发和测试皮肤癌的新治疗方法。Lessin博士一直积极参与指导和培训所有级别的POR学员--医学生、住院医师/研究员和初级教员。这是通过一系列完善的POR计划实现的。目前，莱辛博士在皮肤科的皮肤肿瘤学奖学金计划、NIH培训基金(T32)、药物研究单位、DERM 800研究选修课和初级教师导师计划中担任导师。宾夕法尼亚大学致力于为POR提供必要的机会和设施，这一点是非同寻常的。完善的POR培训核心课程，NIH赞助的普通临床研究中心(GCRC)以及基础和临床研究人员之间的出色互动，为指导和培训个人进行POR提供了一个独特而充满活力的环境。莱辛博士将参加POR核心课程和GCRC。这一奖项将为莱辛博士追求POR并指导POR领域的其他研究人员提供一个关键的基础设施。50%的努力承诺将确保继续获得资金和受保护的时间，用于新疗法的临床测试。此外，它将使莱辛博士能够继续参与正在进行的部门和机构POR计划，并作为宾夕法尼亚大学POR年轻研究人员的榜样和导师。